Ferrari, Samuele http://orcid.org/0000-0003-1122-1231
Beretta, Stefano http://orcid.org/0000-0003-4375-004X
Jacob, Aurelien http://orcid.org/0000-0002-4799-3711
Cittaro, Davide http://orcid.org/0000-0003-0384-3700
Albano, Luisa
Merelli, Ivan
Naldini, Luigi
Genovese, Pietro
Funding for this research was provided by:
Fondazione Telethon (Grant E4, Grant E3)
Ministero della Salute (PE-2016-02363691, E-Rare-3 JTC 2017, GR-2013-02358956)
Ministero dell'Istruzione, dell'Università e della Ricerca (PRIN 2017 Prot. 20175XHBN)
EC | Horizon 2020 Framework Programme (UPGRADE)
Louis-Jeantet Foundation (2019 Jeantet-Collen Prize for Translational Medicine)
Article History
Received: 15 September 2020
Accepted: 26 February 2021
First Online: 24 May 2021
Competing interests
: L.N. and P.G. are inventors of patents on applications of gene editing in HSPCs owned and managed by the San Raffaele Scientific Institute and the Telethon Foundation, including a patent application on improved gene editing filed by S.F., A.J., P.G. and L.N. L.N. is founder and quota holder and P.G. is quota holder of GeneSpire, a startup company aiming to develop ex vivo gene editing in genetic diseases. All other authors declare no competing interests.